Anavex Life Sciences Corp

Short Term Long Term Short Term Comparison Long Term Comparison
  • AVXL
  • 1d-1.51%
  • 1w-3.64%
  • 1m-17.22%
  • 1y-46.32%
ATH
  • ATH Price$28.86
  • ATH Date2021-06-28
  • % since ATH-85.34%
  • % to ATH582.27%
ATL
  • ATL Price$0.64
  • ATL Date2014-11-19
  • % from ATL560.52%
  • Last Low Price$4.23
  • Last Low Date2024-04-15
  • % From Last Low0%
IPO
  • IPO Price$2.00
  • % Current ROI USD211.50%
  • ATH Price$28.86
  • % ROI ATH 450,655.84%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="AVXL"]

Key Data [addtoany]

Current price $4.23
Sector Healthcare
Industry Biotechnology
Today's High/Low $4.3644/$4.175
Volume 1,085,521.00
Previous Close $4.295
52 Week High/Low $10.45/$4.16
Market Cap 352,673,312.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.64
Annualized Dividend $0
$4.23
[addtoany]

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer’s and Parkinson’s diseases.
Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity